Johnson & Johnson
JNJ NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$266.30
KIRA · Stoqly’s AI analyst, in plain words
- Johnson & Johnson had $94.2B of revenue in fiscal 2025, up 6.1% on the year before. Over five years, revenue changed +2.7% a year on average.
- Johnson & Johnson made $26.8B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 7.1% a year.
- Free cash flow was $19.7B in fiscal 2025, 20.9% of revenue.
- Johnson & Johnson returned $18.3B to shareholders in fiscal 2025, 93% of free cash flow. The diluted share count rose 0.0%.
- Johnson & Johnson owes $27.8B more than it holds in cash, about 0.7 years of operating profit.
Market cap
$652.1B
P/E
40.4x
Revenue
$94.2B
Net income
$26.8B
Free cash flow
$19.7B
Operating margin
—
Johnson & Johnson in 30 seconds · fiscal 2025
Are sales growing?
+6.1%
Yes. Sales grew 6.1% last year.
Does it make a profit?
28.5%
Yes. It keeps 28.5% of every sale as profit.
Does profit turn into cash?
20.9%
Yes. 20.9% of sales ends up as free cash.
Is debt under control?
0.7x
Yes. It could repay its debt with 0.7 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
40.4x
One share costs 40.4 times its yearly profit per share. Typical for its sector: 27.9x.
What Johnson & Johnson does
Johnson & Johnson makes prescription medicines and medical devices, sold in virtually every country. Its medicines treat cancer, immune diseases such as psoriasis and Crohn's disease, mental illnesses such as depression and schizophrenia, HIV, high blood pressure in the lungs, and blood clots. Its devices include heart pumps and tools for treating irregular heartbeats and clogged arteries, artificial joints and spine products, surgical instruments and staplers, and ACUVUE contact lenses. It sells to wholesalers, distributors, retailers, hospitals and doctors. Sales were $94.2 billion in 2025. Its medicines segment brought in $60.4 billion, and its MedTech devices segment $33.8 billion. Its biggest product, the multiple myeloma drug DARZALEX, made up about 15.0% of revenue, and STELARA, an immune disease drug now facing competing copies called biosimilars, about 6.5%.
Biggest risks, in its own words
- Generic and biosimilar copies of its key drugs, such as STELARA, and challenges to its patents.
- Healthcare reforms and pricing pressure that could cut what it is paid for its medicines and devices.
- Large legal cases, including product liability suits, that can bring heavy costs, fines and damage to its reputation.
- Delays or failures in developing new medicines and devices.
- Fiscal year ends
- December 28, 2025
- Latest annual report
- 10-K · Feb 11, 2026
- Legal name
- Johnson & Johnson
- CIK
- 0000200406
Johnson & Johnson · JNJ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $78.7B | $80.0B | $85.2B | $88.8B | $94.2B |
| Revenue growth | −4.7% | 1.6% | 6.5% | 4.3% | 6.1% |
| Gross margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Net income | $20.9B | $17.9B | $35.2B | $14.1B | $26.8B |
| Net margin | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| Diluted EPS | $7.81 | $6.73 | $13.72 | $5.79 | $11.03 |
| Cash | |||||
| Cash from operations | $23.4B | $21.2B | $22.8B | $24.3B | $24.5B |
| Capital expenditure | $3.7B | $4.0B | $4.5B | $4.4B | $4.8B |
| Free cash flow | $19.8B | $17.2B | $18.2B | $19.8B | $19.7B |
| FCF margin | 25.1% | 21.5% | 21.4% | 22.3% | 20.9% |
| Dividends paid | $11.0B | $11.7B | $11.8B | $11.8B | $12.4B |
| Share buybacks | $3.5B | $6.0B | $5.1B | $2.4B | $6.0B |
| Share count change | 0.1% | −0.4% | −3.9% | −5.1% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $31.6B | $22.3B | $22.9B | $24.5B | $20.1B |
| Debt incl. finance leases | $33.8B | $39.7B | $29.4B | $36.7B | $47.9B |
| Shareholders' equity | $74.0B | $76.8B | $68.8B | $71.5B | $81.5B |
| Net debt / EBITDA | 0.1x | 0.7x | 0.3x | 0.5x | 0.7x |
| Current ratio | 1.4x | 1.0x | 1.2x | 1.1x | 1.0x |
| Interest coverage | 105.8x | 71.1x | 20.5x | 23.1x | 34.6x |
| Returns and quality | |||||
| Return on capital | 24.0% | 19.5% | 16.5% | 18.5% | 28.6% |
| Return on equity | 30.4% | 23.8% | 48.3% | 20.1% | 35.0% |
| Piotroski F-score | 7 | 4 | 7 | 6 | 4 |
| Altman Z'' | 4.2 | 3.7 | 4.6 | 4.4 | 4.7 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$151M
10 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Johnson & Johnson · JNJ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson JNJ | $652.1B | 6.1% | — | 20.9% | 28.6% | 40.4x | 4 |
| Pfizer PFE | $169.8B | −1.7% | — | 14.5% | 7.3% | 39.2x | 6 |
| AbbVie ABBV | $507.8B | 8.6% | 24.7% | 29.1% | 15.7% | 81.0x | 7 |
| Moderna MRNA | $79.1B | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $266.30 a share, the company is worth $652.1B: 40.4 times its earnings of the last four quarters.
Johnson & Johnson grew sales faster than 2 of its 3 similar companies. Its P/E is higher than 1 of 2.
Source: SEC EDGAR XBRL filings (CIK 0000200406). Data updated October 21, 2026. For information only — not investment advice. Check the original filings before relying on any figure.